J

Johnson & Johnson

Makes prescription drugs and medical devices

IDAR Intern

Summer 2027Deadline 11/9/26
$23.50 - $52.50/hr
Internship
Bachelor's, Master's, MBA
Spring House, PA, USA+2 moreMore locations: Raritan, NJ, USA | Hopewell Township, NJ, USA
HybridHybrid schedule: three days at the assigned New Jersey or Pennsylvania site and two days remotely.
Data & Analytics
No H1B Sponsorship

About the job

Requirements
  • Candidates must have completed their undergraduate freshman year at an accredited university.
  • Candidates must be actively enrolled at an accredited university throughout the internship while pursuing a Bachelor's, Master's, and/or MBA degree in Computer Science, Data Science, Data Engineering, Artificial Intelligence, Machine Learning, Software Engineering, Information Systems, Information Science, Information Technology, Informatics, Analytics, Statistics, Mathematics, Web or User Experience Design, Digital Media, Biomedical Engineering, Life Sciences, or another related technical or scientific discipline.
  • Candidates must have a cumulative GPA of 3.5 or higher across all college coursework.
  • Candidates must be able to work in a hybrid model, attending an assigned Johnson & Johnson site in New Jersey or Pennsylvania three days per week and working remotely two days per week.
  • Candidates must provide their own transportation to and from the assigned work location and arrange their own housing.
  • Candidates must be permanently authorized to work in the United States and must not require employment-visa sponsorship, including H-1B or green-card sponsorship, now or in the future. Students on CPT, OPT, or STEM OPT generally do not meet this requirement unless eligible for an alternative long-term status that does not require company sponsorship.
  • Candidates under 18 may need state-required working papers or other documentation and parental consent for the background check.
Responsibilities
  • Support the design, development, testing, and documentation of AI-enabled solutions, including intelligent agents and AI-based data transformations.
  • Contribute to proof-of-concept solutions, applications, workflows, or automation that improve data integration, operational insights, and user experience.
  • Apply programming and analytical tools such as Python, R, SAS, SQL, APIs, low-code technologies, or approved AI capabilities, as appropriate to the assignment.
  • Prepare, structure, evaluate, and document data used by analytical or AI-enabled solutions.
  • Support solution and model testing while following applicable privacy, security, quality, and compliance expectations.
  • Apply data analytics and automation approaches to clinical development challenges.
  • Support the design, development, and enhancement of the C&SP departmental SharePoint portal.
  • Assess existing content and contribute to improved information architecture, navigation, search, metadata, page layouts, and reusable templates.
  • Create and configure SharePoint pages, web parts, Lists, forms, views, links, and embedded Microsoft Word and Excel content.
  • Develop or enhance Power Automate workflows for departmental processes such as content submissions, approvals, notifications, and reminders.
  • Create or support Power BI dashboards and reports and integrate them into the departmental portal, as appropriate.
  • Support content organization, governance standards, ownership, review cycles, and publishing practices.
  • Support user access and permission management in accordance with applicable security and compliance requirements.
  • Conduct user-centered testing, gather feedback, and implement improvements to usability and accessibility.
  • Review existing content to identify duplicate, outdated, incomplete, or difficult-to-find information and recommend improvements.
  • Partner with C&SP colleagues and cross-functional stakeholders to understand business problems, user needs, and technical requirements.
  • Create project documentation, process maps, user guidance, demonstrations, and presentations.
  • Participate in team meetings, mentoring, networking, and learning activities across IDAR and Global Development.
  • Present project outcomes, lessons learned, and recommendations to stakeholders at the conclusion of the internship.
Desired Qualifications
  • Coursework, academic projects, or practical experience in Artificial Intelligence, Machine Learning, Generative AI, Data Science, or software development.
  • Programming or analytical experience with one or more of Python, R, SAS, SQL, and APIs.
  • Experience with data visualization, automation, or low-code development technologies.
  • Understanding of data structures, data quality, solution testing, or responsible AI principles.
  • Experience or familiarity with Microsoft SharePoint and digital workplace or portal development.
  • Experience with or exposure to SharePoint Pages and Sites, SharePoint Lists, Power Automate, Power BI, Microsoft Excel, Microsoft Word, Forms, embedded content, navigation and search, metadata, and user and permission management.
  • Familiarity with information architecture, content management, web or portal design, or user-centered design concepts.
  • Interest in healthcare, clinical research, pharmaceutical research and development, or global drug development.
  • Leadership or participation in campus programs, research, internships, volunteer activities, or community service.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.